The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.

Richard A Proctor, Annette M Jackson, Vance G Fowler

Abstract read

In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Richard A ProctorEmeritus Professor of Medicine and Medical Microbiology/Immunology, University of Wisconsin School of Medicine and Public Health, 825 Blackfriars Loop, Cary, NC 27519, United States of America. Electronic address: rap@wisc.edu.

Annette M JacksonAssociate Professor of Surgery and Integrative Immunology, DUMC 2645 Duke University School of Medicine, Durham, NC 27710, United States of America. Electronic address: Annette.m.jackson@duke.edu.

Vance G FowlerFlorence McAlister Distinguished Professor of Medicine and Molecular Genetics/Microbiology, Duke Clinical Research Institute, Room 183, Hanes House, 315 Trent Drive, Durham, NC 27710. Duke Box 102359, Hanes House, Trent Drive, Durham, NC 27710, United States of America. Electronic address: Fowler003@mc.duke.edu.

Funding

HLA Fine Mapping to Elucidate S. aureus SusceptibilityR01AI165671 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G., SCOTT, WILLIAM K · 2021 to 2025

$3.8M

NIAID NIH HHS R01 AI165671

6 · The paper itself

Abstract

Development of a vaccine against Staphylococcus aureus has proven to be difficult, in no small measure due to our lack of understanding of the human immune response to this pathogen. Because the human immune response is distinct from other species often used for pre-clinical animal models, including non-human primates, it will be necessary to perform studies in humans to guide vaccine development. One can view the staphylococcal vaccine clinical trials as an opportunity to study human immune response to S. aureus infections, which of course provide outcome data. In order to gain maximal information from these clinical trials, biological materials should be taken during the trial. In this commentary article, we explore a mechanism for such collection.

Indexed as

Clinical Trials as TopicStaphylococcal InfectionsStaphylococcal VaccinesStaphylococcus aureusVaccine DevelopmentAnimalsHumansStaphylococcal VaccinesBiomarkerBiorepositoryClinical trailsHuman immunityStaphylococcus aureusVaccine

Identifiers

PMID40048962

DOI10.1016/j.vaccine.2025.126896

PMCPMC12487812

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.